CTCs in Breast Cancer After Neoadjuvant Treatment and Surgery: a Multicenter, Prospective Clinical Trial
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age18-70
SponsorRenJi Hospital
About this trial
The GILUPI CellCollector® is the first in vivo CTC isolation product worldwide, which is CE approved. This is a prospective, multicenter study to evaluate the prognostic value of circulating tumor cells in breast cancer patients who completed surgery after neoadjuvant treatment.
Eligibility criteria
Qualifiers
Female, aged ≥18 and ≤70 years;
Histologically confirmed invasive breast cancer (cT2-4N0-2M0 or cT1N1-3M0 before neoadjuvant treatment);
Completed neoadjuvant treamtment and surgery (within 4 years after surgery);
Administered neoadjuvant chemotherapy (regardless of chemotherapy regimen);
Disqualifiers
Metastatic disease (Stage IV);
Female patients who are pregnancy or lactation;
Uncontrollable puncture site infection or systemic infection;
Trial design
Treatments tested in this trial
- GILUPI CellCollector®
Treatment groups
484 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov